(Q44582808)

4 December 2017

title

Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis (English)

1 reference

4 December 2017

0 references

1 reference

7

C N Abboud

1 reference

4 December 2017

1

J L Liesveld

1 reference

4 December 2017

J E Lancet

2

1 reference

4 December 2017

K E Rosell

3

1 reference

4 December 2017

A Menon

4

1 reference

4 December 2017

C Lu

5

1 reference

4 December 2017

C McNair

6

1 reference

4 December 2017

J D Rosenblatt

8

1 reference

4 December 2017

publication date

1 September 2003

1 reference

4 December 2017

1 reference

4 December 2017

volume

17

1 reference

4 December 2017

issue

9

1 reference

4 December 2017

page(s)

1806-1812

1 reference

Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403063

RAS and leukemia: from basic mechanisms to gene-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403063

The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403063

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403063

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403063

Inhibitors of protein farnesyltransferase as novel anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403063

Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403063

Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403063

Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403063

7 January 2021

Response of human CD34+ cells to CXC, CC, and CX3C chemokines: implications for cell migration and activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403063

7 January 2021

Effect of nitric oxide production and oxygen tension on progenitor preservation in ex vivo culture

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403063

7 January 2021

Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403063

7 January 2021

Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403063

7 January 2021

Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403063

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403063

1 reference

4 December 2017

1 reference